EA202092360A1 - COMBINATION OF LIF INHIBITORS AND PD-1 AXIS INHIBITORS FOR USE IN THE TREATMENT OF CANCER - Google Patents

COMBINATION OF LIF INHIBITORS AND PD-1 AXIS INHIBITORS FOR USE IN THE TREATMENT OF CANCER

Info

Publication number
EA202092360A1
EA202092360A1 EA202092360A EA202092360A EA202092360A1 EA 202092360 A1 EA202092360 A1 EA 202092360A1 EA 202092360 A EA202092360 A EA 202092360A EA 202092360 A EA202092360 A EA 202092360A EA 202092360 A1 EA202092360 A1 EA 202092360A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
lif
cancer
treatment
combination
Prior art date
Application number
EA202092360A
Other languages
Russian (ru)
Inventor
Жоан Сеоане Суарез
Джудит Анидо Фолгуэйра
Йохан Франссон
Робин Мэттью Халлетт
Моника Паскуаль Гарсиа
Эстер Бонфилл Тейксидор
Эстер Планас Риголь
Original Assignee
Медиммун Лимитед
Фундасио Привада Институт Д'Инвестигасио Онкольохика Де Валь Эброн
Фундасио Привада Институсио Каталана Де Ресерка И Эстудис Аванкатс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медиммун Лимитед, Фундасио Привада Институт Д'Инвестигасио Онкольохика Де Валь Эброн, Фундасио Привада Институсио Каталана Де Ресерка И Эстудис Аванкатс filed Critical Медиммун Лимитед
Priority claimed from PCT/IB2019/000423 external-priority patent/WO2019197903A1/en
Publication of EA202092360A1 publication Critical patent/EA202092360A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В изобретении описаны способы лечения рака с применением комбинаций полипептидов, связывающих лейкоз-ингибирующий фактор (LIF), и ингибиторов оси PD-1.The invention provides methods of treating cancer using combinations of leukemia inhibitory factor (LIF) binding polypeptides and PD-1 axis inhibitors.

EA202092360A 2019-02-22 2019-04-11 COMBINATION OF LIF INHIBITORS AND PD-1 AXIS INHIBITORS FOR USE IN THE TREATMENT OF CANCER EA202092360A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382132 2019-02-22
PCT/IB2019/000423 WO2019197903A1 (en) 2018-04-12 2019-04-11 Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer

Publications (1)

Publication Number Publication Date
EA202092360A1 true EA202092360A1 (en) 2021-02-25

Family

ID=65802026

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092360A EA202092360A1 (en) 2019-02-22 2019-04-11 COMBINATION OF LIF INHIBITORS AND PD-1 AXIS INHIBITORS FOR USE IN THE TREATMENT OF CANCER

Country Status (1)

Country Link
EA (1) EA202092360A1 (en)

Similar Documents

Publication Publication Date Title
EA202092000A1 (en) EGFR DIMERIZATION INHIBITORS AND THEIR USE
PH12020551923A1 (en) Methods and compositions for treating cancer
CO2020009861A2 (en) PD-1 / PD-L1 inhibitors
CL2021000084A1 (en) PD-1 / PD-L1 inhibitors
AU2018278311A1 (en) IRE1 small molecule inhibitors
MX2020012797A (en) Anti-pvrig/anti-tigit bispecific antibodies and methods of use.
EA201891028A1 (en) TRISPECIFIC AND / OR TRIVALENT BINDING PROTEINS FOR PREVENTION OR TREATMENT OF INFECTION CAUSED BY HIV
EA202191852A1 (en) IRREVERSIBLE INHIBITORS OF THE MENIN-MLL INTERACTION
EA201792191A1 (en) FGFR / PD-1 COMBINED THERAPY FOR THE TREATMENT OF MALIGNANT TUMOR
AU2019251289A8 (en) Combination of LIF inhibitors and PD-1 axis inhibitors for use in treating cancer
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
MY185579A (en) Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
MX2024004162A (en) NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS.
EA202191557A1 (en) COMBINED THERAPY WITH RADIOIMMUNOCONJUGATES AND DNA DAMAGE REPAIR INHIBITORS
EA201892287A1 (en) PHARMACEUTICAL COMBINATIONS FOR CANCER TREATMENT
ZA201904533B (en) Antibodies against lif and uses thereof
MX2021008834A (en) Methods of treating breast cancer with tucatinib.
MX2021009863A (en) A dbait molecule in combination with kinase inhibitor for the treatment of cancer.
WO2020033019A3 (en) Novel mct4 inhibitors and uses thereof
MX2023004342A (en) Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors.
WO2019220204A3 (en) Antibodies against lif and dosage forms thereof
MX2020013103A (en) Methods of use of cd24 for the prevention and treatment of leukemia relapse.
MX2021013117A (en) Compositions and methods for treatment of cancer.
EA202092360A1 (en) COMBINATION OF LIF INHIBITORS AND PD-1 AXIS INHIBITORS FOR USE IN THE TREATMENT OF CANCER